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Abstract
Total plasma gamma-glutamyltransferase (GGT) activity is a sensitive, non-specific marker of liver dysfunction. Four GGT
fractions (b-, m-, s-, f-GGT) were described in plasma and their differential specificity in the diagnosis of liver diseases was
suggested. Nevertheless fractional GGT properties have not been investigated yet. The aim of this study was to characterize
the molecular nature of fractional GGT in both human plasma and bile. Plasma was obtained from healthy volunteers;
whereas bile was collected from patients undergoing liver transplantation. Molecular weight (MW), density, distribution by
centrifugal sedimentation and sensitivity to both detergent (deoxycholic acid) and protease (papain) were evaluated. A
partial purification of b-GGT was obtained by ultracentrifugation. Plasma b-GGT fraction showed a MW of 2000 kDa and a
density between 1.063–1.210 g/ml. Detergent converted b-GGT into s-GGT, whereas papain alone did not produce any
effect. Plasma m-GGT and s-GGT showed a MW of 1,000 and 200 kDa, and densities between 1.006-1.063 g/ml and 1.063–
1.210 g/ml respectively. Both fractions were unaffected by deoxycholic acid, while GGT activity was recovered into f-GGT
peak after papain treatment. Plasma f-GGT showed a MW of 70 kDa and a density higher than 1.21 g/ml. We identified only
two chromatographic peaks, in bile, showing similar characteristics as plasma b- and f-GGT fractions. These evidences,
together with centrifugal sedimentation properties and immunogold electronic microscopy data, indicate that b-GGT is
constituted of membrane microvesicles in both bile and plasma, m-GGT and s-GGT might be constituted of bile-acid
micelles, while f-GGT represents the free-soluble form of the enzyme.
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Introduction
c-Glutamyltransferase (GGT, EC 2.3.2.2) is a dimeric glyco-
protein consisting of a heavy and a light subunit linked by non-
covalent bonds. In the N-terminal portion of the heavy subunit a
hydrophobic domain allows the enzyme to be anchored to cell
plasma membrane, with both subunits exposed in the extracellular
environment [1]. GGT catalytic site is localized in the light subunit
and acts on extracellular substrates, such as glutathione (GSH) [2],
leukotriene C4, nitrosoglutathione and other GSH-conjugates
[3,4]. GGT is present in the plasma membrane of virtually all cells,
but it is mainly localized in the epithelial tissues with secretory or
absorptive functions. In adult liver, GGT is localized in the biliary
pole of hepatocytes and in cholangiocytes and hence secreted in
bile [3,5]. Plasma GGT is supposed to origin from liver [6,7] and
early studies demonstrated that it is associated with several carriers
having different molecular weights, densities and charges [8,9].
Nevertheless, the mechanism of release, the structures and the
clinical significance of such carriers have not been completely
characterized.
As regard clinical applications, plasma GGT values over the
upper reference limit (men: 54 U/L, women: 34 U/L) [10] are
found in different types of hepatobiliary diseases, regardless of the
aetiology and alcohol abuse [3]. Studies conducted over the past
10 years have shown that plasma GGT values in the upper part of
the reference range (men.28 U/L; women.19 U/L) [11] are
positively associated with a higher risk of cardiovascular events
[11–13], onset of type II diabetes [14,15] and metabolic syndrome
[16], independently of liver diseases and alcohol consumption.
Nevertheless, the currently used laboratory GGT assay does not
allow the discrimination among the different causes of increased
plasma GGT levels, thus reducing its clinical value and specificity
as a sensitive disease biomarker.
Recently, we developed a sensitive and reproducible method
that allowed us to identify four GGT fractions in plasma of all
healthy subjects, named big-GGT (b-GGT), medium-GGT (m-
GGT), small-GGT (s-GGT) and free-GGT (f-GGT), with
molecular weight (MW) corresponding to 2000, 1000, 250, and
70 kDa, respectively [17]. While f-GGT is the most abundant
fraction in healthy adults [18], the three high MW fractions (b-, m-
and s-GGT) are increased in liver diseases [19]. The first study on
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diagnostic specificity of the four GGT fractions showed that the
latter are present also in patients with non-alcoholic fatty liver
diseases (NAFLD), chronic viral hepatitis C [19] or alcoholic liver
disease [20], but in different quantities. Thus the different GGT
fractions patterns, despite similar total GGT values, allowed the
differential diagnosis [19,20].
The aim of this study was to evaluate the characteristics of
plasma GGT carriers and to show if the enzyme is entire or devoid
of the N-terminal hydrophobic peptide which is thought to be
responsible of the interaction between GGT and the carriers.
Physical properties (i.e. dimension and density), as well as
sensitivity of each fraction to detergent (deoxycholic acid) and
protease (papain) treatment were evaluated. Bile GGT, possibly
contributing to circulating GGT, was also studied.
Materials and Methods
Ethics Statement
The Human Ethics Committee of the University Hospital of
Pisa approved the study; all subjects gave a written informed
consent.
Plasma and bile samples
Aliquots (1–2 ml) from anonymous plasma EDTA samples used
for routine analysis were provided from the Department of
Medical Laboratory of Fondazione Toscana G. Monasterio.
Different samples were pooled to provide suitable volumes for a
more accurate lipoprotein separation and recovery and to obtain
sufficiently concentrated exosome pellets to be analyzed by
immunogold.
Anonymous bile samples (3–8 ml) were obtained from hospi-
talized patients undergoing allogeneic liver transplantation at the
Hepatobiliary Surgery and Liver Transplant Unit of the Univer-
sity Hospital of Pisa. Samples were collected from Kehr’s T tube
placed in the common bile duct during the implant of liver
allograft.
Separation and quantification of GGT fractions
Separation and quantification of GGT fractions were per-
formed on plasma (injection volume Vi: 0.02 ml), plasma
lipoproteins (Vi: 0.05 ml), bile (Vi: 0.02 ml), microparticles (Vi:
0.05 ml) and exosomes (Vi: 0.05 ml) samples, these latter obtained
from both plasma and bile.
All samples were centrifuged (3,000 g, 3 min, 4uC) and
supernatants were filtered using a 0.45 mm PVDF filter. Analysis
of total and fractional GGT was performed as previously described
[17]. Briefly, a fast protein liquid chromatography (FPLC) system
(AKTA purifier; GE Healthcare Europe, Milan, Italy) equipped
with a gel-filtration column (Superose 6 HR 10/300 GL; GE
Healthcare Europe) and a fluorescence detector (Jasco FP-2020;
Jasco Europe, Lecco, Italy) was used. GGT activity was quantified
by post-column injection of the fluorescent substrate for GGT,
gamma-glutamyl-7-amido-4-methylcoumarin (gGluAMC, Nova
Chimica, Milano, Italia). Total area, between 10 and 25 ml
elution volumes, and fractional GGT areas were calculated by a
MatLab program (Version 7 MathWorks, Inc.) to resolve
overlapping peaks. The reaction was calibrated analysing plasma
samples with known total GGT activity (standards); the slope of
the calibration curve was used to convert total and fractional GGT
areas in activity values expressed as U/L.
Determination of total cholesterol
The elution profile of total cholesterol in plasma samples (Vi:
0.05 ml) and lipoprotein preparations (Vi: 0.05 ml) was obtained
by using the same chromatographic procedure described for
fractional GGT analysis. A suitable, commercially available
reagent for total cholesterol determination (Giesse Diagnostic,
Rome, Italy) was used as post-injected reagent. Reaction product
was detected by recording the absorbance at 510 nm.
Plasma lipoprotein separation
Plasma lipoproteins were separated by ultracentrifugation on a
NaBr discontinuous density gradient [21] by using a Beckman
ultracentrifuge with a fixed angle rotor (type 40). Four indepen-
dent plasma pools (5 ml) – each obtained mixing five plasma
aliquots – were examined. This method allowed us to separate
very low-density lipoprotein (VLDL, d,1.006 g/ml), low-density
lipoprotein (LDL, 1.006,d,1.063 g/ml) and high-density lipo-
protein (HDL, 1.063,d,1.21 g/ml). As regard VLDL isolation, a
11.42 mg/ml NaCl solution (1 ml; d = 1.006 g/ml) was added to
plasma pools (5 ml), then they were subjected to ultracentrifugal
separation (100,000 g, 24 h, 20uC) and the VLDL containing
supernatants (0.5 ml) were collected.
LDL isolation was obtained from VLDL-free plasma samples by
adding a 11.42 mg/ml NaCl solution (0.5 ml; d = 1.006 g/ml) and
a 434,80 mg/ml NaBr solution (1 ml; d = 1.3199). Samples,
presenting with a 1.063 g/ml final density, were subjected to
ultracentrifugal separation (100,000 g, 24 h, 20uC) and the LDL
containing supernatants (0.85 ml) were collected. Finally, HDL
isolation was obtained from VLDL- and LDL-free plasma samples
by adding a 85.01 mg/ml NaBr solution (0.850 ml; d = 1.063 g/
ml) and a 644.97 mg/ml NaBr solution (3 ml; d = 1.4705 g/ml).
Samples, presenting with a 1.21 g/ml final density, were subjected
to ultracentrifugal separation (100,000 g, 24 h, 20uC) and the
HDL containing supernatants (0.79 ml) were collected.
Plasma and bile treatment with papain and deoxycholic
acid (DOC)
The cysteine protease papain (Sigma-Aldrich, Milan, Italy) was
pre-incubated with a 25 mM acidic solution of cysteine (Cys-HCl;
3 min, RT) to achieve its full activation. Subsequently, plasma and
bile samples were incubated with activated papain (20 U) for 24 h,
RT under vigorous agitation.
As regard detergent treatment, plasma and bile samples (0.2 ml)
were incubated with DOC (10 g/l, final concentration) for 1 h,
RT under vigorous agitation. This experiment was repeated on
four independent plasma or bile samples.
Isolation of plasma and bile microparticles and exosomes
Isolation of microparticles and exosomes from plasma [22,23]
and bile [24] was performed by a differential centrifugation
procedure. Briefly, samples (1 ml) were diluted to 2 ml with
Dulbecco’s phosphate buffered saline (PBS) and centrifuged at
2,000 g for 10 min at 4uC. Supernatants were then transferred
into ultracentrifuge tubes, further diluted to 7 ml with cold PBS
and centrifuged at 10,000 g for 45 min at 4uC to remove large
debris. Again, supernatants were collected, transferred into
ultracentrifuge tubes and centrifuged at 100,000 g for 2 h. Finally,
the microvesicles-free supernatants were collected and the
exosomes containing pellets were suspended in 0.2 ml of PBS.
This experiment was repeated on five independent plasma samples
and four independent bile samples.
Exosomes preparation for electron microscopy
A plasma pool (100 ml, obtained mixing fifty plasma aliquots)
was diluted with an equal volume of PBS and firstly centrifuged at
2,000 g for 15 min at 15uC. The obtained supernatant was
Gamma-Glutamyltransferase Fractions Analysis
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collected and centrifuged at 15,000 g for 45 min at 15uC. Again,
the post-centrifugal supernatant was recovered, filtered through a
0.22 mm filter to remove lipid aggregates and centrifuged at
100,000 g for 2 h at 15uC. Finally, the exosomes containing pellet
was washed with PBS (100,000 g for 90 min at 15uC) and
suspended in 40 ml of 0.15 M NaCl. Such exosomes suspension
was then layered on 4 ml of a 30% w/v sucrose solution prepared
in NaCl 0.15 M, and centrifuged at 100,000 g for 90 min at 4uC.
A 4 ml aliquot was recovered from the bottom of the tube, diluted
with 15 volumes of 0.15 M NaCl and centrifuged again at
100,000 g for 90 min at 4uC. The final pellet was then fixed in 1%
paraformaldehyde.
A bile pool (120 ml, obtained mixing twenty bile samples) was
diluted with an equal volume of PBS and centrifuged at 2,000 g
for 30 min at 4uC. The obtained supernatant was collected and
further centrifuged at 15,000 g for 30 min at 4uC. Again, the
resulting supernatant was recovered and ultracentrifuged at
100,000 g for 2 h at 4uC. The final pellet was washed with PBS
(100,000 g for 90 min at 4uC) and fixed in 2% paraformaldehyde.
Immunogold electron microscopy and negative staining
Exosomes prepared from both plasma and bile (5 ml) were
placed on an electrically charged (by glow discharge) copper grid
covered with a collodion/amyl acetate membrane. Free aldehyde
groups were saturated with a 50 mM NH4Cl solution in PBS
(5 min, RT). Samples were incubated with a blocking solution
(10% fetal bovine serum (FCS), 20 min, RT), then with a rabbit
polyclonal primary antibody (1:250 in 5% FCS, 1 h, RT) directed
against the C-terminal 20 amino acids of human GGT heavy
chain, and prepared as described [5]. The antigen-antibody
reaction was revealed by using a secondary 15 nm gold particle-
conjugated anti-rabbit IgG antibody (Emsdiasum; 1:40 in 0.5%
FCS, 60 min, RT). All samples were fixed with a 0.5%
glutaraldehyde, 0.15 M NaCl solution (10 min, RT) and nega-
tively stained with uranyl acetate. Finally, samples were examined
under a transmission electron microscope (Philips 410).
Results
Plasma GGT fractions: dimension and density
The comparison between the elution profile of GGT activity
and total cholesterol, performed on the same plasma pool sample
(Fig. 1A), showed that b-GGT and m-GGT fractions eluted with
VLDL (elution volume: 11.3 ml; Stokes radius: 30–80 nm) and
LDL (15.0 ml; 18–25 nm) cholesterol peaks, respectively. The
remaining s-GGT and f-GGT fractions (elution volume 19.0 ml
and 21.0 ml, respectively) presented with an elution profile
partially overlapping the HDL (20 ml; 8–11 nm) cholesterol peak.
On these bases, VLDL lipoprotein (density 0.950–1.006 g/ml),
LDL (density 1.006–1.063 g/ml) and HDL (density 1.063–1.21 g/
ml) were separated by discontinuous density-gradient ultracentri-
fugation and then analysed to evaluate the associated GGT
fractions. Interestingly, b-GGT fraction was mainly recovered with
HDL lipoprotein (Fig. 1D) and in minor quantity with VLDL
lipoprotein (Fig. 1B); m-GGT and s-GGT fractions were
observed only in LDL and HDL samples, respectively (Fig. 1C,
1D); on the contrary, f-GGT fraction was not associated with any
density-gradient lipoprotein fraction, being detectable only in the
lipoprotein-free plasma sample (data not shown). The differential
distribution of GGT fractions according to density was confirmed
in four independent experiments.
Plasma GGT fractions: sensitivity to papain and
deoxycholic acid treatment
In order to better characterize the GGT protein associated with
the four plasma fractions, the presence of the N-terminal,
membrane anchoring peptide of GGT heavy chain was evaluated.
Plasma samples were treated with papain, a cysteine protease
known to promote the release of a soluble, active enzymatic form
of GGT from membranes [25]. Actually, papain treatment did not
affect b-GGT fraction properties, i.e. activity, dimension and gel
filtration elution volume. On the contrary, both m-GGT and s-
GGT fractions were no longer detectable after papain treatment,
all GGT activity being recovered in the f-GGT fraction (Fig. 2A).
Such post-papain f-GGT peak presented with the same elution
volume of untreated plasma f-GGT, but its area was equal to the
sum of m-, s- and f-GGT peaks detectable in the corresponding
untreated plasma.
As regard detergents sensitivity, the treatment of plasma samples
with DOC – an anionic detergent physiologically present in bile –
resulted in the reduction of b-GGT peak with a corresponding
increase of s-GGT fraction, the latter presenting with the same
elution volume of s-GGT in the untreated plasma. On the
contrary, m-GGT and f-GGT fractions were not altered by DOC
treatment (Fig. 2B). Interestingly, when also papain was added to
DOC treated samples all enzymatic activity was recovered in the f-
GGT fraction, (Fig. 2B). Sensitivity to papain and deoxycholic
acid of plasma GGT fractions was confirmed in four independent
experiments.
Bile GGT fractions: sensitivity to papain and deoxycholic
acid treatment
Human bile GGT activity is higher than plasma GGT values
(median: 112.5 U/L, 25u–75u percentile: 73.9–183.2 U/L, min-
max 55.8–218.8 U/L, n = 7). In all examined samples, about 90%
of bile GGT activity was found to be associated with a high MW
fraction corresponding to plasma b-GGT (Fig. 3), while the
remaining part corresponded to plasma f-GGT fraction. Notably,
bile b-GGT peak showed a left side asymmetry, possibly
suggesting a heterogeneous composition of such fraction, due to
the presence of at least two distinct GGT-bearing molecular
complexes: the first, with a higher elution volume/lower molecular
mass, corresponding to plasma b-GGT complex, and the other,
with a lower elution volume/higher molecular mass, detectable
only in bile samples. Treatment of bile with papain resulted in a
partial reduction of b-GGT peak and a corresponding increase of
f-GGT peak (Fig. 3). Similarly to plasma, the combined treatment
with DOC and papain allowed the complete recovery of b-GGT
activity into f-GGT fraction (Fig. 3). Both papain and DOC plus
papain treatments resulted in an increase of total GGT activity in
bile samples (data not shown). Sensitivity to papain and
deoxycholic acid of bile GGT fractions was confirmed in four
independent experiments.
Microparticles and exosomes recovery from plasma and
bile
When samples of isolated plasma microparticles were analysed
by gel filtration chromatography, a GGT activity peak with an
elution volume (10.1 ml) lower than that of plasma b-GGT
fraction (10.9 ml) was detected (Fig. 4). On the other hand, when
samples of isolated plasma exosomes were analysed, we observed a
GGT activity peak with the same elution volume of plasma b-
GGT fraction (10.9 ml). This latter peak was absent in the
corresponding ultracentrifuged exosome-free plasma supernatants,
where only m-, s- and f-GGT fractions were detectable (Fig. 4).
Gamma-Glutamyltransferase Fractions Analysis
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As regard bile samples, all b-GGT activity was recovered in the
pellet containing exosomes, while f-GGT remained in supernatant
(data not shown). These findings were confirmed in five
independent plasma samples and four independent bile samples.
Electron microscopy of exosomes purified from plasma
and bile
Electron microscopy analysis of plasma and bile exosomes
allowed us to confirm the presence of membrane microvesicles
with the typical size of exosomes (20–50 nm). The presence of
GGT protein on part of such microvesicles was confirmed by
immunogold staining (Fig. 5).
Discussion
The main finding of this study is the first characterization of
fractional GGT, which revealed an unexpected complexity.
According to early studies [26], both gel filtration chromatography
and ultracentrifugation procedures revealed a fair analogy
between high molecular weight GGT fractions (b-, m- and s-
GGT) and circulating lipoprotein VLDL, LDL and HDL.
Nevertheless, our results demonstrated that none of the three
GGT fractions could be completely identified with the corre-
sponding class of lipoprotein sharing the same MW. Indeed, if we
exclude s-GGT, all the other GGT fractions have distinctive
features as compared to lipoproteins, and they can be physically
separated from them. These results are against what suggested in
early studies, i.e. that circulating lipoproteins are GGT carriers and
that GGT is too lipophilic to circulate in a free form [26].
Furthermore, we also observed that plasma f-GGT fraction has a
MW corresponding to the free GGT protein, thus demonstrating
that part of plasma GGT do not require any carrier, such as
lipoproteins [26] or albumin [27], to be transported in blood.
Our results showed that plasma b-GGT fraction is constituted
of membrane microvesicles (microparticles and exosomes), b-GGT
dimension and density (30–80 nm; 1.06–1.21 g/ml) being com-
patible with those of membrane microvesicles (40–100 nm; 1.15–
1.27 g/ml) [28]. According to this interpretation, b-GGT was also
shown to be sensitive to DOC action, i.e. a detergent that can
disrupt membrane microvesicles [29], and immunogold analysis
confirmed the association between GGT protein and exosomes.
It was demonstrated that cholesterol-rich micro domains of the
plasma membrane, the so called ‘‘lipid rafts’’, play a crucial role in
processes of exo/endocytosis and in the biogenesis of microves-
icles, and that secreted microvesicles possess high levels of
cholesterol rafts [28,29]. Interestingly, plasma membrane GGT
was found to be specifically localized in lipid rafts, where it is
associated with tetraspanin CD81 [30], i.e. a marker that is usually
Figure 1. GGT-specific (continuous line) and total cholesterol (dashed line) elution profiles in a plasma pool (pool-1) representative
of four experiments, and in the lipoprotein fractions isolated from it. A) Total plasma; B) VLDL (elution volume: 11.3 ml; density 0.950–
1.006 g/ml; Stokes radius: 30–80 nm); C) LDL (15.0 ml; 1.006–1.063 g/ml; 18–25 nm); D) HDL (20.0 ml; 1.063–1.21 g/ml; 8–11 nm). Lipoproteins were
separated by ultracentrifugation on a NaBr discontinuous density gradient. Elution profiles were obtained by size-exclusion chromatography
associated with a post-column reaction specific for GGT or total cholesterol.
doi:10.1371/journal.pone.0088532.g001
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Figure 2. Papain and DOC effects on plasma samples. Effect of papain (25 mmol/l, 24 h, RT) and DOC (1% w/v, 1 h, 37uC) treatments on GGT
fractions in a plasma sample representative of four independent experiments. A) GGT-specific elution profile in the untreated control [continuous
line; GGT activity (U/L): total = 38.8; b-GGT=8.9; m-GGT= 3.1; s-GGT= 14.1; f-GGT= 12.6] and after papain treatment [dotted line; GGT activity (U/L):
total = 49.8; b-GGT= 7.5; m-GGT=n.d.; s-GGT=n.d.; f-GGT= 42.3]. B) GGT-specific elution profile after DOC treatment [dashed line; GGT activity (U/L):
total = 45.0; b-GGT= 1.3; m-GGT= 2.4; s-GGT= 31.2; f-GGT= 10.1] and after DOC and papain treatments [dotted line; GGT activity (U/L): total = 57.0; b-
GGT=n.d.; m-GGT=n.d.; s-GGT=n.d.; f-GGT= 57.0]. n.d.: not detectable.
doi:10.1371/journal.pone.0088532.g002
Figure 3. Papain and DOC effects on bile samples. Effect of
papain (25 mmol/l, 24 h, RT) and DOC (1% w/v, 1 h, 37uC) treatments
on GGT fractions in sample of human bile representative of four
independent experiments. Untreated control [continuous line; GGT
activity (U/L): total = 127.5; b-GGT= 106.2; f-GGT= 21.3], after papain
treatment [dashed line; GGT activity (U/L): total = 171.22; b-GGT= 62.1;
f-GGT= 109.1] and after DOC and papain treatments [dotted line; GGT
activity (U/L): total = 217.6; b-GGT=19.6; f-GGT= 198.0].
doi:10.1371/journal.pone.0088532.g003
Figure 4. GGT activity of isolated microparticles and exosomes.
GGT-specific elution profiles of isolated microparticles (continuous line),
exosomes (dashed line) and microparticles/exosomes-free plasma
(dotted line) samples. Microparticles were obtained from plasma by
centrifugation (10,000 g, 45 min, 4uC) whereas exosomes were
recovered by ultracentrifugation (100,000 g, 2 h, 4uC) of the corre-
sponding microvesicles-free supernatant. Representative chromato-
grams of five independent experiments are reported.
doi:10.1371/journal.pone.0088532.g004
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detectable also in exosomes and microparticles [31]. This
particular localization of GGT may thus help to explain why
such enzyme is released in the extracellular compartment in
association with microvesicles.
More complicated seems to be the biogenesis of the other GGT
fractions (m-GGT, s-GGT and f-GGT) that might arise from
progressive modifications of the b-GGT fraction. In this perspec-
tive our results demonstrated that b-GGT is sensitive to protease
papain only after a pre-treatment with DOC, this possibly
suggesting a protective role of b-GGT phospholipid bilayer on
papain cleavage site. On the other hand, the fact that DOC is able
to convert b-GGT fraction into micelles of s-GGT size suggests
that these latter might be constituted of micelles of bile acids, and
that this conversion would take place in the extracellular
compartment, after b-GGT secretion. Similarly to s-GGT, also
m-GGT fraction appeared to be sensitive to papain but insensitive
to DOC: these characteristics, together with its physical properties
(size, density), suggest that m-GGT could be constituted of micelles
of bile acids with sizes greater than s-GGT ones. Finally, f-GGT
corresponds to the free, soluble form of the enzyme, lacking the N-
terminal anchoring peptide, which is present in all other fractions.
Our results indicate that it could originate directly from both m-
GGT and s-GGT fraction as a consequence of a proteolytic
cleavage.
In this perspective, the analysis of human bile, rather than
solving part of the problem, raised other questions about fractions
composition. Basing on the assumption that both m-GGT and s-
GGT fractions are formed by micelles of bile acids and GGT, we
also compared the human bile fractional profile with that of
human plasma treated with DOC. Unexpectedly, the elution
profile of bile GGT showed the presence of only two fractions,
corresponding to plasma b-GGT and f-GGT. Actually, the lack of
m-GGT and s-GGT fractions may be due to the low bile acids
concentration in hepatic bile, which is about 10 times lower than
the amount of DOC able to convert plasma b-GGT into s-GGT
(1.7 mmol/l vs. 24 mmol/l). Further studies will have to focus on
fractional GGT in gallbladder bile, where bile acids concentration
is 5–10 times higher than that of hepatic bile. Regarding the two
bile fractions, they revealed a greater heterogeneity as compared
to plasma ones. Again f-GGT represents the free enzyme,
nevertheless our data indicate that b-GGT fraction may be
composed of two distinct molecular complexes: the first with
exosomes size and properties, and the other with a size similar to
that of exosomes but sensitive to papain action. Interestingly,
about 80% of biliary GGT activity can be recovered in the
fraction presenting a density of 1.123 g/ml, the richest content of
proteins (55% of total) and bile acids (35%), but showing the lowest
amount of phospholipids (17%) and, even, undetectable levels of
cholesterol [32]. This composition seems to suggest that this
papain-sensitive part of bile b-GGT could be composed of bile
acid micelles.
Another specific property of fractional bile GGT is that
following papain treatment – either in the presence or in the
absence of DOC – the total amount of GGT activity recovered in
the resulting f-GGT fraction was higher than expected. It can be
envisaged that the molecular context surrounding biliary GGT
may alter not only its sensitivity to proteases, but also the kinetic of
the enzyme activity, e.g. by influencing the accessibility of the GGT
substrate to the active site of the enzyme [33].
Against this background, it is clear that a better knowledge of
physical and molecular properties of fractional plasma GGT
would help both to understand their role in the pathogenesis of
diseases, and to improve their clinical utilization as biomarkers of
disease. In vitro studies demonstrated that different cell types release
b-GGT in culture medium [34] as well as upon activation [35]. It
can be hypothesized that also in vivo several GGT expressing
tissues may contribute to b-GGT in plasma and in other biological
fluids. Proteomic analysis revealed that microvesicles have a
unique protein composition that varies depending on cellular
origin [36]: the identification of cell specific markers in the b-GGT
fraction would thus allow the identification of major tissues
contributing to plasma GGT in all the pathological conditions
associated with its elevation.
Fractional GGT analysis of plasma obtained from healthy
subjects, patients with non-alcoholic fatty liver disease, viral or
alcoholic chronic hepatitis showed the presence of the same four
GGT fractions but with different amount of associated GGT
activity [18–20]. This suggests that different disease status might
Figure 5. GGT localization on exosomes by transmission electron microscopy. Exosomes from A) plasma and B) bile were incubated with a
primary antibody directed against GGT and with a secondary 15 nm gold particle-conjugated antibody. After fixation with glutaraldehyde, samples
were negatively stained with uranyl acetate and examined under a transmission electron microscope.
doi:10.1371/journal.pone.0088532.g005
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influence the availability of carriers but not their interaction with
the enzyme. Similarly, we showed in this study that bile samples
were characterized by the presence of the same two GGT fractions
(b-GGT and f-GGT) indicating a shared mechanism of release.
Our results allowed us to have a first look inside the nature of
fractional GGT, but further studies will be required to fully
characterize their exact composition and the compartments in
which they are generated.
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